For the tens of millions of Americans who cannot push their LDL cholesterol (trivially known as "bad cholesterol") low enough on statins alone, the strongest backup has meant needles. That changed on July 16, 2026, when the U.S. Food and Drug Administration approved the first oral PCSK9 inhibitor, a class of powerful cholesterol drugs that until now existed only as an injection.

Merck & Co. (NYSE:MRK) won that race with Lipfendra, and the approval matters to two very different audiences at once. It hands high-risk patients a once-daily tablet instead of a syringe, and it hands investors a fresh growth story with real competitive stakes.

A Pill That Does An Injection’s Job

PCSK9 inhibitors work by blocking a protein that keeps LDL receptors from clearing cholesterol from the blood, and they are among the most effective LDL-lowering drugs available. The catch has always been delivery, because the two established options, Amgen Inc.’s (NASDAQ:AMGN) Repatha and the Praluent sold by Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi, are antibodies that patients inject every two or four weeks.

Lipfendra, known generically as enlicitide, delivers similar firepower in a once-daily 20-milligram tablet. In its pivotal trials, the drug cut LDL cholesterol by roughly 57% against placebo, landing in the same range as the injectables it aims to replace. Because it is an ordinary pill covered under the pharmacy benefit, it moves through retail and mail-order pharmacies rather than requiring refrigeration or a clinic visit.

Who Are The Biggest Winners?

The clearest winners are patients who need more than a statin and have resisted the needle. That includes people with heterozygous familial hypercholesterolemia, a genetic condition that drives LDL dangerously high, along with the large group who remain above their target despite maximum statin therapy or who cannot tolerate statins at all.

With this pill, the chances of these people adhering to their drugs are much higher. With a once daily pill that fits into a routine that already includes other tablets, patients who balked at self-injection now have a reason to keep going. Better adherence to LDL-lowering therapy tends to translate into fewer cardiovascular events over time, which is the entire point of treating high cholesterol in the first place.

The potential market is enormous for a reason that has little to do with efficacy. Millions of Americans on statins never reach their LDL target, and a share of them stall there because the next step has meant an injection they were unwilling to start. Removing the needle removes one of the most common reasons patients and doctors settle for a number that is still too high. If even a fraction of that group steps up to an oral PCSK9 inhibitor, the treated population grows well beyond the niche the injectables carved out.

The Price Tag And The Evidence Gap

Merck set a list price of about $315 a month, or roughly $3,800 a year, which undercuts the roughly $700 to $900 monthly list prices of the injectable antibodies by about two-thirds. List prices are not what most insured patients pay, since rebates and copay assistance lower the real cost, yet a lower starting point still gives Merck room to compete on both access and out-of-pocket burden. Anyone considering the drug should confirm where it falls on their plan’s formulary and whether prior authorization is required, because coverage rules will determine the actual price at the counter.

However, there is an important caveat regarding this drug. Lipfendra earned approval on its ability to lower LDL, not yet on proof that it prevents heart attacks and strokes, since the large cardiovascular outcomes trial is still running. The LDL reduction is a strong signal, and the injectable PCSK9 drugs have shown outcomes benefits, but the definitive event data for the pill is not in hand.

What It Means For Your Portfolio

For Merck, the timing is strategic. The company faces the impending loss of patent protection for its cancer blockbuster Keytruda late this decade, and a first-in-class cardiovascular pill targeting one of the largest chronic-disease markets in medicine is exactly the kind of addition its portfolio needs. Cholesterol treatment reaches an enormous population, and an oral option priced below the incumbents could expand the class well beyond where injections took it.

That expansion is a threat to the incumbents. Amgen leans on Repatha as a key growth driver, and Regeneron shares Praluent with Sanofi, so a cheaper, needle-free rival with comparable potency pressures both franchises. The competitive map also includes Novartis with the twice-yearly injection Leqvio and Esperion Therapeutics Inc. (NASDAQ:ESPR) with its oral non-statin pill, each of which now competes for the same patients who are not at goal.

The bull case for Merck rests on convenience, price, and a huge addressable market. The risks are equally clear, since pending outcome data, aggressive formulary negotiations, and rebate economics could all cap how much pricing power the launch really has.

What To Watch From Here

Patients who remain above their LDL goal, especially those who have avoided the injectable options, now have a reason to revisit the conversation with their doctor. Investors have a cleaner scorecard, since early prescription uptake, formulary placement, and the eventual cardiovascular outcomes results will show whether the first cholesterol pill becomes a blockbuster or merely a convenient alternative.

None of this is investment advice, and readers weighing either the medication or the stocks should confirm current details with their physician, their insurer, and their own research before acting.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.